Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 462 participants.

Also called NCT01301833

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 462 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01301833
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01301833. Non-randomized; no masking; primary purpose treatment. Start 2011-02 (registry gives no type); primary completion 2012-09 (actual). Results posted on 2015-08-28.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
teneligliptin
Intervention (Drug)
glinide
Intervention (Drug)
biguanide
Intervention (Drug)
alpha-glucosidase inhibitor
Lead sponsor
Tanabe Pharma Corporation (class: industry)

Record details

Record id
cardio:ct-nct01301833
Content hash
0d739827f35b16d2b34f49b3ca22b24b359c9a85864201b3d4f5a2b80630bb51